{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:21:13Z","timestamp":1783484473306,"version":"3.55.0"},"reference-count":38,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["ClinicalTrials.gov identifier: NCT01695005"],"award-info":[{"award-number":["ClinicalTrials.gov identifier: NCT01695005"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Drug Safety"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Deregulated Notch signaling is implicated in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Crenigacestat (LY3039478) prevents cleavage of Notch proteins and may benefit patients with relapsed or refractory NHL or CLL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This phase I clinical trial assessed the safety and efficacy of crenigacestat in patients with relapsed or refractory NHL and CLL. The main objectives were to characterize the safety profile, to confirm the recommended phase II dose of crenigacestat in patients with hematological malignancies, and to assess preliminary antitumor activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A phase I trial enrolling patients with relapsed or refractory NHL and CLL, with Notch tumor alteration based on molecular or immunohistochemistry tumor pre-screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Eligible patients received crenigacestat 50\u2009mg orally three times per week, for a 28-day cycle, until disease progression or unacceptable toxicity. Tumor responses were assessed using the Revised Response Criteria for Malignant Lymphoma and the National Cancer Institute Working Group for CLL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Overall, 62 patients (40 with NHL and 22 with CLL) were pre-screened for a Notch alteration. Notch alteration was identified in 21\/62 (34%) of patients pre-screened. Nine patients (five with peripheral T-cell NHL and three with CLL) with Notch alteration were eligible for the clinical trial and treated. The most common adverse events in all grades of severity were diarrhea (56%), nausea (56%), platelet count decrease (44%), and fatigue (33%). One patient (11%) with peripheral T-cell lymphoma obtained a partial response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Crenigacestat demonstrated a modest clinical activity at the recommended dose in adult patients with relapsed or refractory NHL or CLL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>NCT01695005.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20420986241311461","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T10:29:14Z","timestamp":1753957754000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Notch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3482-3331","authenticated-orcid":false,"given":"Jean-Marie","family":"Michot","sequence":"first","affiliation":[{"name":"D\u00e9partement d\u2019Innovation Th\u00e9rapeutique et des Essais Pr\u00e9coces, Gustave Roussy, Universit\u00e9 Paris-Saclay, 114 rue Edouard Vaillant, 94800 Villejuif, France"},{"name":"Department of Hematology, Gustave Roussy, Universit\u00e9 Paris-Saclay, 114 rue Edouard Vaillant, 94800 Villejuif, France"},{"name":"INSERM, U1170, Gustave Roussy, Universit\u00e9 Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsofia","family":"Balogh","sequence":"additional","affiliation":[{"name":"Experimental and Translational Pathology Platform (PETRA), AMMICa, INSERM US23\/CNRS UMS3655, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[{"name":"Hematology Department, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Innovation Th\u00e9rapeutique et des Essais Pr\u00e9coces, Gustave Roussy, Universit\u00e9 Paris-Saclay, Villejuif, France"},{"name":"Department of Hematology, Gustave Roussy, Universit\u00e9 Paris-Saclay, Villejuif, France"},{"name":"INSERM, U1170, Gustave Roussy, Universit\u00e9 Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Innovation Th\u00e9rapeutique et des Essais Pr\u00e9coces, Gustave Roussy, Universit\u00e9 Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rastislav","family":"Bahleda","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Innovation Th\u00e9rapeutique et des Essais Pr\u00e9coces, Gustave Roussy, Universit\u00e9 Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Quivoron","sequence":"additional","affiliation":[{"name":"Translational Research Hematological Laboratory, AMMICA, INSERM US23\/CNRS UMS3655, Gustave Roussy Cancer Campus, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Ammari","sequence":"additional","affiliation":[{"name":"Biomaps, UMR1281 INSERM, CEA, CNRS, Department of Radiology, Gustave Roussy Cancer Campus, Universit\u00e9 Paris-Saclay, Villejuif, France"},{"name":"ELSAN Department of Radiology, Institut de Canc\u00e9rologie Paris Nord, Sarcelles, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Scoazec","sequence":"additional","affiliation":[{"name":"Experimental and Translational Pathology Platform (PETRA), AMMICa, INSERM US23\/CNRS UMS3655, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim A.","family":"Benhadji","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Massard","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Innovation Th\u00e9rapeutique et des Essais Pr\u00e9coces, Gustave Roussy, Universit\u00e9 Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32407-2"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S34273"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15412"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24076"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.1.5.159"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5415.770"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1186"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-007-7164-1"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature10113"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2832"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-138172"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.2789"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.238766"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells10010016"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.11.049"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy244"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.08.012"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00739-x"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33188"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_3_4_22_2","first-page":"5446","volume-title":"Blood","volume":"111","author":"Hallek M","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111(12): 5446\u20135456."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-11-201006010-00232"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20110921"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-1215"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067306"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012386"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002995"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.116855"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1458-7"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-403626"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33739-2"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.80"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.1540"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29055"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03659"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13727"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.8282"},{"key":"e_1_3_4_39_2","first-page":"819","article-title":"Notch inhibitors induce diarrhea, hypercrinia and secretory cell metaplasia in the human colon","volume":"20","author":"Collins M","year":"2021","unstructured":"Collins M, Michot JM, Bellanger C, et al. Notch inhibitors induce diarrhea, hypercrinia and secretory cell metaplasia in the human colon. EXCLI J 2021; 20: 819\u2013827.","journal-title":"EXCLI J"}],"container-title":["Therapeutic Advances in Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420986241311461","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20420986241311461","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420986241311461","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:40:45Z","timestamp":1777592445000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20420986241311461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":38,"alternative-id":["10.1177\/20420986241311461"],"URL":"https:\/\/doi.org\/10.1177\/20420986241311461","relation":{},"ISSN":["2042-0986","2042-0994"],"issn-type":[{"value":"2042-0986","type":"print"},{"value":"2042-0994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"article-number":"20420986241311461"}}